These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recent advances in thrombotic thrombocytopenic purpura. Sadler JE; Moake JL; Miyata T; George JN Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695 [TBL] [Abstract][Full Text] [Related]
4. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura. Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302 [TBL] [Abstract][Full Text] [Related]
5. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. George JN Clin Adv Hematol Oncol; 2005 Aug; 3(8):627-32. PubMed ID: 16167049 [TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Lian EC Semin Thromb Hemost; 2005 Dec; 31(6):625-32. PubMed ID: 16388413 [TBL] [Abstract][Full Text] [Related]
7. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Schwameis M; Schörgenhofer C; Assinger A; Steiner MM; Jilma B Thromb Haemost; 2015 Apr; 113(4):708-18. PubMed ID: 25503977 [TBL] [Abstract][Full Text] [Related]
8. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura. Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376 [TBL] [Abstract][Full Text] [Related]
9. [ADAMTS13, von Willebrand factor specific cleaving protease]. Veyradier A; Coppo P Med Sci (Paris); 2011 Dec; 27(12):1097-105. PubMed ID: 22192749 [TBL] [Abstract][Full Text] [Related]
10. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura. Budde U; Schneppenheim R Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251 [TBL] [Abstract][Full Text] [Related]
11. Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies. Soejima K; Nakagaki T Semin Hematol; 2005 Jan; 42(1):56-62. PubMed ID: 15662617 [TBL] [Abstract][Full Text] [Related]
12. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. Groot E; Fijnheer R; Sebastian SA; de Groot PG; Lenting PJ J Thromb Haemost; 2009 Jun; 7(6):962-9. PubMed ID: 19548905 [TBL] [Abstract][Full Text] [Related]
13. Identification of ADAMTS13 Inhibitors in Acquired TTP. Favaloro EJ; Chapman K; Mohammed S; Vong R; Pasalic L Methods Mol Biol; 2023; 2663():505-521. PubMed ID: 37204733 [TBL] [Abstract][Full Text] [Related]
14. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Schiviz A; Wuersch K; Piskernik C; Dietrich B; Hoellriegl W; Rottensteiner H; Scheiflinger F; Schwarz HP; Muchitsch EM Blood; 2012 Jun; 119(25):6128-35. PubMed ID: 22529289 [TBL] [Abstract][Full Text] [Related]
15. Inherited ADAMTS13 mutations associated with Thrombotic Thrombocytopenic Purpura: a short review and update. Markham-Lee Z; Morgan NV; Emsley J Platelets; 2023 Dec; 34(1):2138306. PubMed ID: 36281781 [TBL] [Abstract][Full Text] [Related]
16. Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura. Deforche L; Tersteeg C; Roose E; Vandenbulcke A; Vandeputte N; Pareyn I; De Cock E; Rottensteiner H; Deckmyn H; De Meyer SF; Vanhoorelbeke K PLoS One; 2016; 11(8):e0160388. PubMed ID: 27479501 [TBL] [Abstract][Full Text] [Related]
17. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Tsai HM Kidney Int Suppl; 2009 Feb; (112):S11-4. PubMed ID: 19180123 [TBL] [Abstract][Full Text] [Related]
19. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Furlan M; Robles R; Solenthaler M; Lämmle B Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594 [TBL] [Abstract][Full Text] [Related]
20. Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. Lotta LA; Lombardi R; Mariani M; Lancellotti S; De Cristofaro R; Hollestelle MJ; Canciani MT; Mannucci PM; Peyvandi F J Thromb Haemost; 2011 Sep; 9(9):1744-51. PubMed ID: 21726405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]